A phase II study of pemetrexed in chemotherapy-naïve elderly patients aged ≥75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003)

Japanese Journal of Clinical Oncology

Volumn 43, Issue 12, 2013, Pages 1184-1189

  Hattori, Yoshihiro ^a   Iwasaku, Masahiro ^b   Satouchi, Miyako ^a   Nishiyama, Akihiro ^b   Korogi, Yohei ^b   Otsuka, Kojiro ^c   Fujita, Shiro ^d   Katakami, Nobuyuki ^d   Mori, Masahide ^e   Nishino, Kazumi ^f   Morita, Satoshi ^g   Negoro, Shunichi ^a  

^a HYOGO CANCER CENTER   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy na ve; Elderly; Non small cell lung cancer; Pemetrexed; Phase II study

Indexed keywords

CRIZOTINIB; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID; PEMETREXED;

ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; GERIATRIC DISORDER; HISTOLOGY; HUMAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMOKING; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CHEMOTHERAPY-NAÏVE; ELDERLY; NON-SMALL-CELL LUNG CANCER; PEMETREXED; PHASE II STUDY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 84888985529     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt159     Document Type: Article

References (11)

1. Kaneko S, Ishikawa KB, Yoshimi I, et al. Projection of lung cancer mortality in Japan. Cancer Sci 2003;94:919-23.
2. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
3. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-72.
4. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63.
5. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276s-80s.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
7. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63.
8. Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007;2:221-9.
9. Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-11.
10. Abe T, Yokoyama A, Takeda K, et al. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L. ASCO Meeting Abstracts 2011;29:7509.
11. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88.